Vitasora Health Limited

As of June 30, 2025, Vitasora Health Limited carries a market capitalization of 61.50M, placing it among publicly traded companies globally. Its enterprise value stands at 61.14M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vitasora Health Limited's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2025, Vitasora Health Limited has 1.58B shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 17.59, and the price-to-book ratio stands at 4.19.

These figures are as of June 30, 2025. The EV/Sales ratio of 19.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 61.14M versus a market cap of 61.50M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Vitasora Health Limited maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Vitasora Health Limited posted a negative return on equity (ROE) of -117.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -74.29, reflecting losses generated across the asset base. Inventory turnover of 0.01 indicates how many times Vitasora Health Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Vitasora Health Limited recorded 1,236.00 in income tax expense. The company reported a pretax loss of -10.10M and -10.11M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Vitasora Health Limited's stock has declined approximately 53.85% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

Over the twelve months ended June 30, 2025, Vitasora Health Limited generated 3.09M in revenue and converted that into -10.11M in net income, yielding earnings per share of -0.01. EBITDA reached -10.66M, while operating income came in at -10.72M.

As of June 30, 2025, Vitasora Health Limited holds 419,371.00 in cash and equivalents against 57,418.00 in total debt, resulting in a net debt position of -394,240.00. Total book value stands at 14.67M, with working capital of 1.67M providing operational flexibility.

Over the twelve months ended June 30, 2025, Vitasora Health Limited posted a gross margin of 99.03, reflecting its pricing power and cost economics. The operating margin of -346.33 and net profit margin of -326.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -12.46, meaning Vitasora Health Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Vitasora Health Limited's most recent stock split took place on May 23, 2016 with a 47:48 split ratio.

As of June 30, 2025, Vitasora Health Limited has an Altman Z-Score of -34.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.